The VICC.ORG Investigator Directory

Eric L. Grogan, M.D., M.P.H.

Assistant Professor of Thoracic Surgery
Investigator, Institute for Medicine and Public Health
VICC Member
Thoracic Surgeon

Patient Contact Information:

The Vanderbilt Clinic
1301 Medical Center Dr., Suite 1710
Nashville, TN 37232-5734
Appointments: 615-322-0064
Further Information: 615-322-0248
Fax: 615-343-5993

Nashville Veterans Affairs Medical Center
1310 24th Ave. South
Nashville , TN 37212-2637
Phone: 615-327-4751
Fax: 615-873-7901

Healthcare Provider Contact Information:

Vanderbit Medical Center
609 Oxford House, 1313 21st Avenue South
Nashville, TN 37232-4682


Dr. Grogan's clinical practice includes all areas of general thoracic surgery. He has experience in the treatment of lung and esophageal cancer, lung failure surgery, lung transplantation, mediastinal tumors, and tracheal and bronchoplastic procedures. Dr. Grogan's clinical interests have focused on minimally invasive thoracic surgery for treatment of lung cancer and benign esophageal diseases. He performs VATS lobectomies, radiotracer guided excision of small pulmonary nodules, and laparoscopic and thoracoscopic esophageal surgical procedures.

Dr. Grogan was born in Charlottesville, Virginia and raised in Paducah, Kentucky. He attended Lipscomb University in Nashville, TN and graduated summa cum laude in 1995. In 1999, he received his medical degree with honors from Vanderbilt University. After completing a general surgery internship and residency at Vanderbilt, Dr. Grogan continued his cardiothoracic surgery training at the University of Virginia where he also was the minimally invasive thoracic fellow. During his surgical training, he also obtained a Master's in Public Health from Vanderbilt University focusing on surgical outcomes research and quality improvement.

Dr. Grogan's current research focuses on the early detection and optimal therapy for patients with lung cancer. He holds a secondary appointment with the Department of Medicine and the Institute for Medicine and Public Health.

Dr. Grogan joined the Vanderbilt University faculty in 2008. He serves as the chief of Thoracic Surgery at Nashville VA Hospital.


  • B.S. Lipscomb University, Summa Cum Laude, 1995
  • M.D., Vanderbilt University School of Medicine, Alpha Omega Alpha, 1999
  • M.P.H., Vanderbilt University School of Medicine, 2004

Research Specialty:

My interests are using proteomics, genomics, and epidemiology to develop personalized diagnostic and treatment options for patients with lung cancer. In addition we are evaluating the most effective new strategies for the diagnosis and treatment of lung cancer.

Research Description:

A recently recruited member of the Department of Thoracic Surgery, Eric L. Grogan, M.D., M.P.H., has also been awarded the VPSD grant. His grant entitled “Predicting Lung Cancer with a Serum Protein Test” is a translational research project that is using serum proteomics, epidemiology, and imaging techniques to predict lung cancer in patients with pulmonary nodules. “With the increasing use of Computed Tomography (CT scan), we are finding more pulmonary nodules. Most of these nodules are benign, but some are malignant and determining which ones are cancerous is challenging. Currently we use a combination of the patient’s risk factors and imaging to decide which nodules are high risk for cancer and need surgical excision. However, 20 percent of our operations on these suspicious nodules result in a benign diagnosis. This puts our patients at risk and is costly to the medical system.”

“Using a multidisciplinary approach, we have a team of basic scientists, translational scientists pulmonologists, thoracic surgeons, epidemiologists, and health economists. We are working together to develop a cost-effective blood test for patients with suspected lung cancer. Dr. Pierre Massion’s laboratory (VICC Spore Grant) has developed a simple blood test that can predict patients who have all stages of lung cancer. Using MALDI – MS techniques, they have identified a seven protein signature that is highly predictive of lung cancer. Together, we are determining the accuracy of this serum proteomic test in patients with lung nodules and are combining this serum proteomic test with the patient’s risk factors and imaging characteristics. A highly specific test will help reduce unnecessary surgery while not missing any cases of lung cancer. We are also evaluating the accuracy of this test in predicting lung cancer recurrence.”


You do not have JavaScript enabled. This site works better with JavaScript turned on.